Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A team at UC Riverside discovered a way to deliver chemotherapy drug paclitaxel to targeted cancer cells via molecular Trojan horse 123B9, which targets EphA2 oncogene. This approach reduced circulating cancer cells and metastasis in animal models.
The studies reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. Larotrectinib had rapid, potent, and durable anti-tumor activity in children and adults with solid tumors and TRK fusions.
A phase 1/2 trial of larotrectinib found that three-quarters of patients with advanced cancers responded to the treatment, which targets a specific genetic mutation. The therapy has shown promise in treating pediatric patients with TRK-positive cancer, including infantile fibrosarcoma, and offers a potential cure for some cases.
A new drug, larotrectinib, has been shown to be effective in treating cancers with specific genetic mutations. The study found that 75% of patients with TRK fusion-positive cancers responded to the treatment, with 13% achieving a complete response.
Researchers at Scripps Research Institute developed a quick method to modify dozens of drugs or molecules, improving disease-fighting properties. The approach, called click chemistry, was found to increase the potency of three cancer drugs under lab conditions.
A study found that patients with advanced cancer were less capable of making treatment decisions than healthy adults, but doctors often overestimated their competence. The research suggests a shift in patient-doctor relationships, emphasizing the importance of respecting patient autonomy while ensuring decision-making capacity.
A systematic review and meta-analysis found that pediatric phase I cancer trials have improved outcomes for approximately 1 in 10 children, with a fatal drug-related complication rate of 2.09%. The study's results suggest refining risk/benefit assessments for these trials.
A study of nearly 800 postmenopausal women found that four commonly used prognostic breast cancer tests have varying abilities to predict disease recurrence. The tests, including Oncotype Dx and Prosigna Risk of Recurrence Score, were compared for their accuracy in predicting whether the cancer will return after five years.
Researchers at Karolinska Institutet in Sweden have identified three molecules that effectively treat over 60 types of cancer cells without harming normal cells. These molecules target the TrxR1 enzyme, which supports cancer cell growth and protects them from oxidative stress.
Researchers at WashU Medicine developed a new approach to combat cervical cancer by targeting the tumor's fuel supply. A combination of radiation and three drugs that cut off glucose metabolism effectively shuts down tumor metabolism, making it vulnerable to treatment.
In a Penn-led trial, cabozantinib significantly shrunk tumors in 34 out of 35 patients with metastatic, radioactive iodine-resistant thyroid cancer. The median time on the study was 35 weeks, and 54% of patients achieved a partial response.
Jean-Charles Soria, a leading cancer researcher, has been awarded the TAT 2018 Honorary Award for his groundbreaking contributions to cancer drug development. His work has led to increased response rates and successful drug approvals, including osimertinib for lung cancer.
The study identified specific 'metastatic variant enhancer loci' that drive cancer cell metastasis, and showed that inhibiting these enhancers can halt the spread of tumor cells. Blocking expression of individual genes regulated by these enhancers also diminished metastatic capacity.
Researchers developed a novel approach to studying cancer, grouping 32 types of cancer into 10 classes based on molecular pathways. This understanding can lead to new diagnosis and treatment methods, including identifying neuroendocrine tumors that may be missed with current markers.
A recent neutron analysis of glaucoma drugs and their interaction with human carbonic anhydrase II (hCA II) enzyme revealed the impact of temperature, pH, and electrical charge on drug targeting. The study provides new information about hydrogen-bonding networks in hCA II, which may aid in designing more effective cancer treatments.
Researchers at Cold Spring Harbor Laboratory have discovered that a widely-studied cancer gene called MELK does not play a crucial role in cancer cell growth. The team's findings suggest that inherent flaws in scientific techniques used to link MELK to cancer led to the error.
Combining a blood test for high alpha fetoprotein (AFP) levels with ultrasound imaging improves liver cancer detection by 40 percent, according to researchers at UT Southwestern Medical Center. Early detection is crucial for improving survival rates in patients with liver cancer, which is on the rise in the US.
A multidisciplinary team of Penn researchers will investigate immune system response to cancers and develop new therapies for gynecologic cancers. The team will examine how patients vary in their responses to different anti-cancer therapies and identify key factors contributing to treatment success.
A phase 3 clinical trial showed apalutamide treatment significantly delayed metastasis development in men with prostate cancer resistant to standard therapy. The treatment also improved survival and reduced disease progression symptoms.
Researchers at UPMC Hillman Cancer Center have identified a new genetic change in the estrogen receptor that contributes to therapy resistance in ER-positive breast cancer. The presence of ESR1 fusion proteins in treatment-resistant breast cancer may lead to improved treatments for this form of the disease.
A global study found that treating multiple chronic diseases is putting a significant financial burden on countries' health systems and individuals. Patients with multimorbidity often face high out-of-pocket costs, leading to non-adherence to prescribed medicines.
Researchers at Boston University School of Medicine have found that individual BET bromodomain proteins work independently, reducing the effectiveness of pan-BET inhibitors. This discovery paves the way for more fine-tuned experiments and treatments in breast cancer patients with varying levels of protein expression.
Researchers at Hong Kong Baptist University have designed and synthesized a smart globular macromolecular machine vehicle for actively controlled cancer drug delivery, enhancing the efficacy of targeted therapy drugs. The breakthrough offers insights into targeted therapies such as Chlorambucil in leukemia treatment.
Researchers have developed a new method to grow patient-derived xenografts (PDX) liver cancer cells in culture, which maintains their proper shape and function and grows as organoids. The success of the engineered organoids has the potential to revolutionize the screening and development of liver cancer drugs.
A team of computer scientists has developed a new system to rapidly determine which cancer drugs are likely to work best given a patient's genetic markers. eGARD, the first publicly available system of its kind, can match genetic signatures with outcomes with 95 percent precision.
Researchers at H. Lee Moffitt Cancer Center identified a new target to reduce the risk of graft-versus-host disease (GVHD) in stem cell transplants. The JAK2 inhibitor pacritinib has been shown to minimize GVHD while maintaining antitumor response.
Researchers have found that the loss of a tumor suppressor in triple-negative breast cancer provides clues for novel treatments. Drugs targeting PLK1, AURK and CHK1 may be effective for 20-30% of patients with RB-deficient tumors.
Researchers at Arizona State University have discovered that ibrutinib can also target ERBB4, a lesser-studied member of the RTK family, potentially thwarting solid tumor growth. The compound limits growth in human cancer cells and reduces tumor size in mice.
A Canadian Medical Association Journal study has found genetic variants associated with diseases and adverse drug reactions in 56 healthy participants. The results suggest that whole genome sequencing can benefit Canada's health care, but also highlight potential pitfalls and the need for careful evaluation.
A new study reveals how basal cell cancer responds to treatment and offers new ideas for controlling this disease. The researchers found that the relative location of a cell within a tumor can have a big effect on its sensitivity to drug treatment.
Researchers at the University of Tokyo developed a blood vessel-on-a-chip technology that recreates a human blood vessel and shows how new capillaries grow from a single vessel. The technology can be used to develop drugs targeting angiogenesis, which is a key process in cancer growth.
Researchers at Georgetown University Medical Center used a novel approach to find that the FDA-approved drug clofarabine can shut down Ewing sarcoma cells in lab tests. The study suggests that clofarabine may be effective in treating this rare and aggressive cancer, which primarily affects young people.
Researchers at Osaka University have developed a computational method that reveals chemoresistance drug targets by integrating gene expression level and DNA methylation modification data. The approach identifies TRAF4 as an important gene for chemoresistance in gastrointestinal cancer, including esophageal cancer.
The Data Science Institute at Columbia has awarded grants to five research teams to use data science to solve societal problems in cancer research, medical science, transportation and technology. The teams will work together to transform several fields throughout the university.
A team of scientists from the National University of Singapore has developed a way to wirelessly deliver light into deep regions of the body to activate light-sensitive drugs for photodynamic therapy (PDT). The technology enables PDT to be used on inner organs with fine control, potentially treating a wider range of cancers.
Huntsman Cancer Institute has been selected as a NCI Center for patient-derived model development, utilizing cutting-edge research to test new drugs and drug combinations for breast cancer. The goal is to provide data to prioritize clinical trials and help determine why certain drugs work for some people and others do not.
Researchers have found that PD-1 inhibitors can be effective in treating supratentorial pediatric ependymoma, a type of brain cancer with poor prognosis. The study identified RELA-fusion as a genetic cause and showed that these tumors express high levels of PD-L1, which can be targeted by PD-1 inhibitors.
A recent study presented at the American Stroke Association's International Stroke Conference found that cancer patients with stroke are less likely to receive standard clot-busting medication compared to those without a malignancy. The use of newer procedures to mechanically remove clots, however, shows a similar trend in both groups.
Cancer researchers have identified CDK12 inhibitors as a potential treatment option for Ewing sarcoma, a rare and aggressive childhood cancer. The inhibitors show promise in killing Ewing sarcoma cells and can be combined with PARP inhibitors to increase effectiveness. This breakthrough brings hope to the pediatric oncology field, whic...
Researchers at Queen Mary University of London have successfully modified a common flu virus to target and kill pancreatic cancer cells. The new technique could potentially become a promising new treatment for patients with the aggressive disease.
Researchers have made significant progress in treating non-small cell lung cancer (NSCLC) with the development of molecularly targeted therapies and immunotherapies. These treatments aim to attack tumor cells with mutated genes, but resistance is a common challenge.
A study published in British Journal of Clinical Pharmacology analyzed herbal product interactions with prescription medications. The analysis revealed significant adverse drug reactions, particularly among patients taking warfarin and statins for cardiovascular complications.
A panel of experts has issued new guidelines for molecular diagnostic testing and treatment decisions in lung cancer. The updates reflect recent advancements and decades of work to identify the genetic underpinnings of lung cancer, helping oncologists match patients with effective therapies.
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers. The compounds were tested on micro-tumors and showed effectiveness against specific cancers, giving hope for developing new drugs to fight cancer.
The foundation awarded grants to early career scientists with 'high-risk/high-reward' ideas who lack preliminary data, aiming to significantly impact cancer prevention, diagnosis, and treatment. The recipients will use prebiotics to manipulate the microbiota, develop novel degraders for targeted therapies, and investigate tumor T cells...
Scientists have revealed the atomic-level structure of a molecular complex responsible for modifying proteins, which could lead to new medications for cancer and other diseases. The complex, known as OST, plays a key role in protein glycosylation, a process linked to numerous human body functions.
The study provides the first atomic description of the herpes virus associated with Kaposi's sarcoma, allowing scientists to identify specific targets for antiviral therapies. This breakthrough could lead to the development of new treatments for both KSHV and Epstein-Barr viruses.
Researchers have identified a new precision medicine approach for metastatic pancreatic cancer, analyzing tumor RNA to match patients with targeted drugs. The approach has shown clinical responses in three of four patients, targeting 'master regulator proteins' responsible for cancer cell survival.
Scientists from King's College London have discovered a new drug combination that effectively awakens the immune system to attack cancer. The breakthrough involves combining chemotherapy with a drug trialled for neonatal jaundice, which targets an enzyme called Heme Oxygenase-1 (HO-1) and promotes tumour growth.
Researchers used Cryo-EM to capture images of molecular machinery called RNA Polymerase III in unprecedented detail, revealing five key stages in which the complex reshapes itself to successfully transcribe the DNA code. This discovery could open up new approaches to cancer treatment by targeting the complex's activity.
A randomized controlled trial found that systematic bright light exposure improved sleep efficiency and self-reported sleep quality in fatigued cancer survivors. The intervention showed significant effects compared to dim light exposure.
The NHS bowel scope screening programme saw a significant increase in uptake when patients were sent additional reminders addressing common concerns, highlighting the importance of patient information and support., Bowel cancer is the 4th most common cancer in the UK, with over half of cases diagnosed at a late stage.
RAS molecules act in pairs, known as dimers, to cause cancer and transmit signals that tell a cell to grow and divide. The study provides a foundation for further studies on RAS biology and could potentially pave the way to develop new cancer drugs.
Researchers found that activating REV-ERB proteins can starve cancer cells by blocking nutrient production, while normal cells are not affected. The discovery sheds light on a new uncharacterized way to treat cancer with limited toxicity.
A recent study by Queen Mary University of London found that protein markers are a more accurate predictor of patient responses to midostaurin, a new leukemia treatment. This breakthrough could lead to double the number of patients being treated and improve outcomes for those with acute myeloid leukemia.
Researchers have identified MED1 as a key player in HER2-driven breast cancer development and spread. The study found that mutating MED1 disrupted its interaction with the estrogen receptor, significantly delaying tumor growth and cancer stem-like cell formation.
A study found that new treatments and screening methods have reduced breast cancer deaths by 49% since 2012, compared to 37% in 2000. The reduction is largely due to advances in treatment, with screening contributing 31-48% depending on the molecular subtype.
A recent study by USC researchers found that survival among adolescents and young adults with cancer has not improved over the past three decades. The study breaks down cancer survival rates by race, ethnicity, age group, socioeconomic status, and cancer stage, highlighting disparities in health outcomes.
The UC Santa Cruz Genomics Institute's Treehouse Childhood Cancer Initiative has received a $500,000 grant to conduct a 24-month registry study evaluating the effectiveness of comparative RNA-seq analysis in pediatric cancer treatment. The project aims to assess the impact on clinical decision-making and patient outcomes.
Manning's research focuses on the role of retinoblastoma protein in regulating chromosome segregation. Her work aims to understand how defects in this process contribute to genetic variability and chemotherapy resistance in tumors. The study may lead to new targets for anti-cancer medications.